nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRK1—Progesterone—uterine cancer	0.365	0.518	CbGbCtD
Naltrexone—UGT1A1—Etoposide—uterine cancer	0.16	0.227	CbGbCtD
Naltrexone—ABCB1—Progesterone—uterine cancer	0.0708	0.1	CbGbCtD
Naltrexone—ABCB1—Dactinomycin—uterine cancer	0.0562	0.0796	CbGbCtD
Naltrexone—ABCB1—Etoposide—uterine cancer	0.0317	0.0449	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—uterine cancer	0.0216	0.0306	CbGbCtD
Naltrexone—Lethargy—Epirubicin—uterine cancer	0.000268	0.00091	CcSEcCtD
Naltrexone—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000268	0.00091	CcSEcCtD
Naltrexone—Nausea—Progesterone—uterine cancer	0.000267	0.000908	CcSEcCtD
Naltrexone—Pain in extremity—Epirubicin—uterine cancer	0.000263	0.000892	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000263	0.000892	CcSEcCtD
Naltrexone—Feeling abnormal—Dactinomycin—uterine cancer	0.000262	0.00089	CcSEcCtD
Naltrexone—Ill-defined disorder—Etoposide—uterine cancer	0.000262	0.000889	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00026	0.000884	CcSEcCtD
Naltrexone—Hot flush—Doxorubicin—uterine cancer	0.00026	0.000882	CcSEcCtD
Naltrexone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000259	0.000881	CcSEcCtD
Naltrexone—Increased appetite—Doxorubicin—uterine cancer	0.000259	0.000878	CcSEcCtD
Naltrexone—Migraine—Epirubicin—uterine cancer	0.000258	0.000878	CcSEcCtD
Naltrexone—Menopausal symptoms—Doxorubicin—uterine cancer	0.000257	0.000875	CcSEcCtD
Naltrexone—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.000874	CcSEcCtD
Naltrexone—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.000873	CcSEcCtD
Naltrexone—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000255	0.000868	CcSEcCtD
Naltrexone—Malaise—Etoposide—uterine cancer	0.000254	0.000864	CcSEcCtD
Naltrexone—Face oedema—Epirubicin—uterine cancer	0.000253	0.000861	CcSEcCtD
Naltrexone—Purpura—Doxorubicin—uterine cancer	0.000252	0.000856	CcSEcCtD
Naltrexone—Abdominal pain—Dactinomycin—uterine cancer	0.000251	0.000854	CcSEcCtD
Naltrexone—Body temperature increased—Dactinomycin—uterine cancer	0.000251	0.000854	CcSEcCtD
Naltrexone—Loss of consciousness—Etoposide—uterine cancer	0.000248	0.000842	CcSEcCtD
Naltrexone—Lethargy—Doxorubicin—uterine cancer	0.000248	0.000842	CcSEcCtD
Naltrexone—Cough—Etoposide—uterine cancer	0.000246	0.000836	CcSEcCtD
Naltrexone—Convulsion—Etoposide—uterine cancer	0.000244	0.00083	CcSEcCtD
Naltrexone—Dehydration—Epirubicin—uterine cancer	0.000244	0.00083	CcSEcCtD
Naltrexone—Hypertension—Etoposide—uterine cancer	0.000244	0.000827	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000243	0.000825	CcSEcCtD
Naltrexone—Pain in extremity—Doxorubicin—uterine cancer	0.000243	0.000825	CcSEcCtD
Naltrexone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.000823	CcSEcCtD
Naltrexone—Chest pain—Etoposide—uterine cancer	0.00024	0.000816	CcSEcCtD
Naltrexone—Abdominal pain upper—Epirubicin—uterine cancer	0.00024	0.000815	CcSEcCtD
Naltrexone—Migraine—Doxorubicin—uterine cancer	0.000239	0.000812	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000238	0.00081	CcSEcCtD
Naltrexone—Discomfort—Etoposide—uterine cancer	0.000237	0.000806	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000236	0.000803	CcSEcCtD
Naltrexone—Nasopharyngitis—Epirubicin—uterine cancer	0.000235	0.000798	CcSEcCtD
Naltrexone—Face oedema—Doxorubicin—uterine cancer	0.000235	0.000797	CcSEcCtD
Naltrexone—Hypersensitivity—Dactinomycin—uterine cancer	0.000234	0.000796	CcSEcCtD
Naltrexone—Confusional state—Etoposide—uterine cancer	0.000232	0.000789	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000232	0.000787	CcSEcCtD
Naltrexone—Anaphylactic shock—Etoposide—uterine cancer	0.00023	0.000782	CcSEcCtD
Naltrexone—Infection—Etoposide—uterine cancer	0.000229	0.000777	CcSEcCtD
Naltrexone—Asthenia—Dactinomycin—uterine cancer	0.000228	0.000775	CcSEcCtD
Naltrexone—Influenza—Epirubicin—uterine cancer	0.000227	0.000771	CcSEcCtD
Naltrexone—Dehydration—Doxorubicin—uterine cancer	0.000226	0.000768	CcSEcCtD
Naltrexone—Tachycardia—Etoposide—uterine cancer	0.000225	0.000763	CcSEcCtD
Naltrexone—Skin disorder—Etoposide—uterine cancer	0.000224	0.00076	CcSEcCtD
Naltrexone—Hyperhidrosis—Etoposide—uterine cancer	0.000223	0.000756	CcSEcCtD
Naltrexone—Abdominal pain upper—Doxorubicin—uterine cancer	0.000222	0.000754	CcSEcCtD
Naltrexone—Angina pectoris—Epirubicin—uterine cancer	0.000221	0.000751	CcSEcCtD
Naltrexone—Anorexia—Etoposide—uterine cancer	0.000219	0.000746	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000219	0.000743	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—uterine cancer	0.000218	0.000741	CcSEcCtD
Naltrexone—Diarrhoea—Dactinomycin—uterine cancer	0.000218	0.000739	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—uterine cancer	0.000217	0.000738	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000214	0.000728	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000211	0.000717	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—uterine cancer	0.00021	0.000713	CcSEcCtD
Naltrexone—Paraesthesia—Etoposide—uterine cancer	0.000207	0.000702	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—uterine cancer	0.000206	0.000702	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—uterine cancer	0.000205	0.000697	CcSEcCtD
Naltrexone—Dyspnoea—Etoposide—uterine cancer	0.000205	0.000697	CcSEcCtD
Naltrexone—Somnolence—Etoposide—uterine cancer	0.000205	0.000695	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—uterine cancer	0.000205	0.000695	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—uterine cancer	0.000203	0.000691	CcSEcCtD
Naltrexone—Infestation—Epirubicin—uterine cancer	0.000202	0.000687	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—uterine cancer	0.000202	0.000687	CcSEcCtD
Naltrexone—Vomiting—Dactinomycin—uterine cancer	0.000202	0.000687	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—uterine cancer	0.000202	0.000686	CcSEcCtD
Naltrexone—Rash—Dactinomycin—uterine cancer	0.000201	0.000681	CcSEcCtD
Naltrexone—Decreased appetite—Etoposide—uterine cancer	0.0002	0.00068	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Etoposide—uterine cancer	0.000199	0.000675	CcSEcCtD
Naltrexone—Fatigue—Etoposide—uterine cancer	0.000198	0.000674	CcSEcCtD
Naltrexone—Pain—Etoposide—uterine cancer	0.000197	0.000669	CcSEcCtD
Naltrexone—Constipation—Etoposide—uterine cancer	0.000197	0.000669	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—uterine cancer	0.000197	0.000668	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—uterine cancer	0.000197	0.000668	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000195	0.000663	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—uterine cancer	0.000191	0.00065	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—uterine cancer	0.000191	0.000649	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—uterine cancer	0.000191	0.000648	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—uterine cancer	0.00019	0.000645	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—uterine cancer	0.00019	0.000645	CcSEcCtD
Naltrexone—Feeling abnormal—Etoposide—uterine cancer	0.00019	0.000644	CcSEcCtD
Naltrexone—Nausea—Dactinomycin—uterine cancer	0.000189	0.000642	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—uterine cancer	0.000188	0.00064	CcSEcCtD
Naltrexone—Gastrointestinal pain—Etoposide—uterine cancer	0.000188	0.00064	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—uterine cancer	0.000187	0.000636	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—uterine cancer	0.000187	0.000636	CcSEcCtD
Naltrexone—Urticaria—Etoposide—uterine cancer	0.000183	0.000621	CcSEcCtD
Naltrexone—Body temperature increased—Etoposide—uterine cancer	0.000182	0.000618	CcSEcCtD
Naltrexone—Abdominal pain—Etoposide—uterine cancer	0.000182	0.000618	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—uterine cancer	0.000182	0.000618	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—uterine cancer	0.000182	0.000618	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—uterine cancer	0.000182	0.000617	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—uterine cancer	0.00018	0.000612	CcSEcCtD
Naltrexone—Naloxone—ESR1—uterine cancer	0.000179	1	CrCbGaD
Naltrexone—Connective tissue disorder—Epirubicin—uterine cancer	0.000178	0.000606	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000177	0.000602	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—uterine cancer	0.000177	0.0006	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—uterine cancer	0.000176	0.000597	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—uterine cancer	0.00017	0.000577	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—uterine cancer	0.00017	0.000576	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—uterine cancer	0.000169	0.000575	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—uterine cancer	0.000169	0.000573	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—uterine cancer	0.000168	0.000571	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—uterine cancer	0.000167	0.000567	CcSEcCtD
Naltrexone—Asthenia—Etoposide—uterine cancer	0.000165	0.000561	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—uterine cancer	0.000165	0.000561	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—uterine cancer	0.000165	0.00056	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—uterine cancer	0.000164	0.000557	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—uterine cancer	0.000164	0.000556	CcSEcCtD
Naltrexone—Chills—Epirubicin—uterine cancer	0.000163	0.000554	CcSEcCtD
Naltrexone—Pruritus—Etoposide—uterine cancer	0.000163	0.000553	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—uterine cancer	0.00016	0.000545	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—uterine cancer	0.000159	0.000541	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—uterine cancer	0.000158	0.000537	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—uterine cancer	0.000157	0.000535	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—uterine cancer	0.000157	0.000534	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—uterine cancer	0.000157	0.000532	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—uterine cancer	0.000156	0.00053	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—uterine cancer	0.000156	0.000529	CcSEcCtD
Naltrexone—Tension—Epirubicin—uterine cancer	0.000155	0.000527	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—uterine cancer	0.000155	0.000526	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—uterine cancer	0.000154	0.000522	CcSEcCtD
Naltrexone—Back pain—Epirubicin—uterine cancer	0.000153	0.00052	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—uterine cancer	0.000152	0.000518	CcSEcCtD
Naltrexone—Dizziness—Etoposide—uterine cancer	0.000152	0.000517	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—uterine cancer	0.000152	0.000516	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—uterine cancer	0.000152	0.000516	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—uterine cancer	0.000151	0.000515	CcSEcCtD
Naltrexone—Chills—Doxorubicin—uterine cancer	0.000151	0.000512	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—uterine cancer	0.000149	0.000506	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—uterine cancer	0.000148	0.000505	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—uterine cancer	0.000147	0.0005	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—uterine cancer	0.000147	0.000498	CcSEcCtD
Naltrexone—Vomiting—Etoposide—uterine cancer	0.000146	0.000497	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—uterine cancer	0.000146	0.000497	CcSEcCtD
Naltrexone—Agitation—Epirubicin—uterine cancer	0.000145	0.000494	CcSEcCtD
Naltrexone—Rash—Etoposide—uterine cancer	0.000145	0.000493	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—uterine cancer	0.000145	0.000493	CcSEcCtD
Naltrexone—Headache—Etoposide—uterine cancer	0.000144	0.00049	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—uterine cancer	0.000144	0.00049	CcSEcCtD
Naltrexone—Tension—Doxorubicin—uterine cancer	0.000144	0.000488	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—uterine cancer	0.000143	0.000487	CcSEcCtD
Naltrexone—Malaise—Epirubicin—uterine cancer	0.000143	0.000484	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—uterine cancer	0.000142	0.000483	CcSEcCtD
Naltrexone—Syncope—Epirubicin—uterine cancer	0.000142	0.000482	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—uterine cancer	0.000142	0.000481	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—uterine cancer	0.000141	0.000478	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—uterine cancer	0.00014	0.000475	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—uterine cancer	0.000139	0.000472	CcSEcCtD
Naltrexone—Cough—Epirubicin—uterine cancer	0.000138	0.000469	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—uterine cancer	0.000138	0.000468	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—uterine cancer	0.000137	0.000465	CcSEcCtD
Naltrexone—Nausea—Etoposide—uterine cancer	0.000137	0.000465	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—uterine cancer	0.000136	0.000464	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—uterine cancer	0.000136	0.000461	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—uterine cancer	0.000135	0.000457	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—uterine cancer	0.000135	0.000457	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—uterine cancer	0.000135	0.000457	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—uterine cancer	0.000134	0.000457	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—uterine cancer	0.000134	0.000456	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000134	0.000454	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—uterine cancer	0.000133	0.000452	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—uterine cancer	0.000132	0.000448	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—uterine cancer	0.000132	0.000447	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—uterine cancer	0.000131	0.000446	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—uterine cancer	0.00013	0.000442	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—uterine cancer	0.000129	0.000439	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—uterine cancer	0.000129	0.000438	CcSEcCtD
Naltrexone—Oedema—Epirubicin—uterine cancer	0.000129	0.000438	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—uterine cancer	0.000129	0.000437	CcSEcCtD
Naltrexone—Infection—Epirubicin—uterine cancer	0.000128	0.000436	CcSEcCtD
Naltrexone—Cough—Doxorubicin—uterine cancer	0.000128	0.000434	CcSEcCtD
Naltrexone—Shock—Epirubicin—uterine cancer	0.000127	0.000431	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—uterine cancer	0.000127	0.000431	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—uterine cancer	0.000127	0.00043	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—uterine cancer	0.000126	0.000429	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—uterine cancer	0.000126	0.000428	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—uterine cancer	0.000125	0.000426	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—uterine cancer	0.000125	0.000424	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—uterine cancer	0.000125	0.000423	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—uterine cancer	0.000125	0.000423	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—uterine cancer	0.000125	0.000423	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—uterine cancer	0.000124	0.000422	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000124	0.00042	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—uterine cancer	0.000123	0.000418	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—uterine cancer	0.000123	0.000418	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—uterine cancer	0.000122	0.000414	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—uterine cancer	0.00012	0.000409	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—uterine cancer	0.000119	0.000406	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—uterine cancer	0.000119	0.000406	CcSEcCtD
Naltrexone—Infection—Doxorubicin—uterine cancer	0.000119	0.000403	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000118	0.000399	CcSEcCtD
Naltrexone—Shock—Doxorubicin—uterine cancer	0.000117	0.000399	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—uterine cancer	0.000117	0.000398	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—uterine cancer	0.000117	0.000397	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—uterine cancer	0.000117	0.000396	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—uterine cancer	0.000116	0.000394	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—uterine cancer	0.000116	0.000394	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—uterine cancer	0.000115	0.000392	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—uterine cancer	0.000115	0.000391	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—uterine cancer	0.000115	0.00039	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—uterine cancer	0.000114	0.000387	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—uterine cancer	0.000112	0.000381	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000111	0.000378	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—uterine cancer	0.000111	0.000378	CcSEcCtD
Naltrexone—Pain—Epirubicin—uterine cancer	0.00011	0.000375	CcSEcCtD
Naltrexone—Constipation—Epirubicin—uterine cancer	0.00011	0.000375	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000109	0.00037	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—uterine cancer	0.000108	0.000367	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—uterine cancer	0.000107	0.000364	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—uterine cancer	0.000106	0.000362	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—uterine cancer	0.000106	0.000361	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—uterine cancer	0.000106	0.000361	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—uterine cancer	0.000106	0.000358	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—uterine cancer	0.000104	0.000353	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000103	0.00035	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—uterine cancer	0.000103	0.00035	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—uterine cancer	0.000103	0.000348	CcSEcCtD
Naltrexone—Pain—Doxorubicin—uterine cancer	0.000102	0.000347	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—uterine cancer	0.000102	0.000347	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—uterine cancer	0.000102	0.000347	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—uterine cancer	0.000102	0.000347	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—uterine cancer	9.84e-05	0.000334	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—uterine cancer	9.76e-05	0.000332	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—uterine cancer	9.51e-05	0.000323	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—uterine cancer	9.48e-05	0.000322	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—uterine cancer	9.44e-05	0.000321	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—uterine cancer	9.44e-05	0.000321	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—uterine cancer	9.26e-05	0.000315	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—uterine cancer	9.13e-05	0.00031	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—uterine cancer	8.83e-05	0.0003	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—uterine cancer	8.8e-05	0.000299	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—uterine cancer	8.57e-05	0.000291	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—uterine cancer	8.53e-05	0.00029	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—uterine cancer	8.45e-05	0.000287	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—uterine cancer	8.2e-05	0.000279	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—uterine cancer	8.17e-05	0.000278	CcSEcCtD
Naltrexone—Rash—Epirubicin—uterine cancer	8.14e-05	0.000276	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—uterine cancer	8.13e-05	0.000276	CcSEcCtD
Naltrexone—Headache—Epirubicin—uterine cancer	8.08e-05	0.000275	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—uterine cancer	7.89e-05	0.000268	CcSEcCtD
Naltrexone—Nausea—Epirubicin—uterine cancer	7.66e-05	0.00026	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—uterine cancer	7.59e-05	0.000258	CcSEcCtD
Naltrexone—Rash—Doxorubicin—uterine cancer	7.53e-05	0.000256	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—uterine cancer	7.52e-05	0.000256	CcSEcCtD
Naltrexone—Headache—Doxorubicin—uterine cancer	7.48e-05	0.000254	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—uterine cancer	7.09e-05	0.000241	CcSEcCtD
